Potential role of cinnamaldehyde and costunolide to counteract metabolic syndrome induced by excessive fructose consumption

被引:12
作者
Rashwan, Ayat S. [1 ]
El-Beltagy, Marwa A. [1 ]
Saleh, Sherif Y. [1 ]
Ibrahim, Ibrahim A. [1 ]
机构
[1] Suez Canal Univ, Dept Biochem, Fac Vet Med, Ismailia, Egypt
关键词
Metabolic syndrome; Fructose; Cinnamaldehyde; Costunolide; Insulin resistance; INSULIN-RESISTANCE; OXIDATIVE STRESS; TRANS-CINNAMALDEHYDE; ETHANOLIC EXTRACT; NATURAL-PRODUCTS; LIVER-INJURY; METFORMIN; RATS; INFLAMMATION; ATTENUATION;
D O I
10.1186/s43088-019-0025-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
BackgroundOne of the serious public health problems in the world is metabolic syndrome. It includes visceral obesity, dyslipidemia, insulin resistance, hyperglycemia, and hypertension. As a contributor to almost all the classic signs of metabolic syndrome, fructose was the ideal choice. There are certain shortcomings with existing drugs for insulin-resistant treatment. Plants still represent the main source of most available medicines. Cinnamaldehyde (CNA) is an active principle of Cinnamomum zeylanicum. Costunolide (CE) is natural sesquiterpene lactones, which is the main bioactive constituent of Saussurea lappa. The main aim of the present study is to investigate the effect of the synthetic antidiabetic agent (metformin) in comparison with natural constituents (cinnamaldehyde, costunolide) after developing a reliable model for insulin resistance by using high fructose diet (HFD).ResultsIt was found that HFD increased plasma glucose, insulin, glycosylated hemoglobin, HbA1c, serum total cholesterol, LDL-cholesterol, triglyceride, ALT, AST, creatinine, and uric acid. Moreover, HFD decreased hepatic reduced glutathione and superoxide dismutase levels. While oral administration of cinnamaldehyde and costunolide significantly decreased plasma glucose, HbA1c, total cholesterol, LDL-cholesterol, triglyceride, and increased level of hepatic reduced glutathione and superoxide dismutase activity. Also, cinnamaldehyde and costunolide restored the altered plasma levels of ALT, AST, creatinine, and uric acid to normal.ConclusionsThe results of this experimental study showed that cinnamaldehyde and costunolide could be used as safe drugs for treating different abnormalities of metabolic syndrome.
引用
收藏
页数:8
相关论文
共 61 条
  • [1] Cinnamaldehyde ameliorates STZ-induced rat diabetes through modulation of IRS1/PI3K/AKT2 pathway and AGEs/RAGE interaction
    Abdelmageed, Marwa E.
    Shehatou, George S.
    Abdelsalam, Rami A.
    Suddek, Ghada M.
    Salem, Hatem A.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 (02) : 243 - 258
  • [2] Ahmed MA, 2018, EGYPTIAN J HOSP MED, V71, P2885, DOI [10.12816/0045837, DOI 10.12816/0045837]
  • [3] Insulinotropic effect of cinnamaldehyde on transcriptional regulation of pyruvate kinase, phosphoenolpyruvate carboxykinase, and GLUT4 translocation in experimental diabetic rats
    Anand, Prachi
    Murali, K. Y.
    Tandon, Vibha
    Murthy, P. S.
    Chandra, Ramesh
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2010, 186 (01) : 72 - 81
  • [4] Ashwini S, 2017, PHARMACOGN RES, V9, P51, DOI 10.4103/0974-8490.199766
  • [5] Babu PS, 2007, PHYTOMEDICINE, V14, P15, DOI 10.1016/j.phymed.2006.11.005
  • [6] Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats
    Bagul, Pankaj K.
    Middela, Harish
    Matapally, Saidulu
    Padiya, Raju
    Bastia, Tanmay
    Madhusudana, K.
    Reddy, B. Raghunath
    Chakravarty, Sumana
    Banerjee, Sanjay K.
    [J]. PHARMACOLOGICAL RESEARCH, 2012, 66 (03) : 260 - 268
  • [7] Berger S., 1976, FUNDAMENTALS CLIN CH
  • [8] BEUTLER E, 1963, J LAB CLIN MED, V61, P882
  • [9] Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review
    Caliceti, Cristiana
    Calabria, Donato
    Roda, Aldo
    Cicero, Arrigo F. G.
    [J]. NUTRIENTS, 2017, 9 (04):
  • [10] Chan D. C., 2016, Metabolic Syndrome: A Comprehensive Textbook, P525, DOI [10.1007/978-3-319-11251-0_30, DOI 10.1007/978-3-319-11251-0_30]